Methods and compositions for the prevention or treatment of Barth syndrome
D. Travis Wilson, Newton, MA (US); and Mark Bamberger, South Glastonbury, CT (US)
Assigned to STEALTH BIOTHERAPEUTICS INC., Needham, MA (US)
Filed by STEALTH BIOTHERAPEUTICS INC., Needham, MA (US)
Filed on Jul. 9, 2021, as Appl. No. 17/371,475.
Application 17/371,475 is a continuation of application No. 16/929,370, filed on Jul. 15, 2020, granted, now 11,083,772.
Application 16/929,370 is a continuation of application No. 15/626,255, filed on Jun. 19, 2017, granted, now 11,083,771.
Application 15/626,255 is a continuation of application No. 14/771,408, granted, now 9,687,519, issued on Jun. 27, 2017, previously published as PCT/US2014/019622, filed on Feb. 28, 2014.
Claims priority of provisional application 61/771,642, filed on Mar. 1, 2013.
Claims priority of provisional application 61/771,534, filed on Mar. 1, 2013.
Claims priority of provisional application 61/839,753, filed on Jun. 26, 2013.
Prior Publication US 2021/0401923 A1, Dec. 30, 2021
1. A method for increasing or normalizing the 18:2 cardiolipin species in a mammalian subject having Barth Syndrome comprising administering to the subject a therapeutically effective amount of the peptide D-Arg-2′6′-Dmt-Lys-Phe-NH2, or a pharmaceutically acceptable salt thereof.